Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Isentress · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| HAART+Raltegravir 12 months (+/-) Maraviroc | EXPERIMENTAL | - |
| HAART | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Isentress® | DRUG | P.O, 1 tablet containing 400 mg every 12 hours |
| Celsentri® | DRUG | p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA) |
Inclusion Criteria: * Male or female patients, aged over 18 years * HIV infection confirmed by Western Blot * Karnofsky score \> 80% * Treatment-experienced patients having received combined antiretroviral therapy including at least 2 RTI and 1 PI/r for at least 12 months with plasma viral load \<5...
Top 20 of 28 competitors
Isentress is an investigational small molecule being studied for the treatment of HIV Infections. It is being evaluated in a Phase 3 clinical trial to assess the impact of therapy intensification on the lymphoid reservoir for HIV-1 in chronically infected patients. The drug is not yet approved and remains in clinical development.
Isentress is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this small molecule for the treatment of HIV Infections, with the drug currently in Phase 3 development.
Isentress is in Phase 3 clinical development for HIV Infections. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
Isentress is being studied in one completed Phase 3 clinical trial with the identifier NCT00935480. This trial, titled IntensVIH, enrolled 17 participants in France and evaluated the impact of therapy intensification by an integrase inhibitor on the lymphoid reservoir for HIV-1 in chronically infected patients.
Isentress is the brand name for the drug raltegravir, an integrase inhibitor used in the treatment of HIV Infections. The clinical trial NCT00935480 refers to therapy intensification by an integrase inhibitor, which corresponds to the mechanism of action of raltegravir, the active ingredient in Isentress.